Quereda C, Teruel J L, Lamas S, Marcén R, Matesanz R, Ortuño J
Nephron. 1987;45(2):104-10. doi: 10.1159/000184088.
The evolution of serum ferritin levels in 111 chronic-hemodialysis patients is prospectively studied. Patients were classified in two groups according to the presence or absence of 'hemochromatosis antigens' (HLA A3, B7 or B14) in their HLA typing. Levels of serum ferritin were similar in both groups before they started dialysis and during the first year. On the contrary, in the second and third hemodialysis years serum ferritin was higher in the group carrying 'hemochromatosis antigens'. These differences were observed in patients treated with parenteral iron either in the form of transfusions or as intravenous dextran-iron but not in patients receiving oral iron. We conclude that the risk of developing iron overload is greater in hemodialysis patients with HLA A3, B7 or B14. Nevertheless, this potential risk can be minimized with a restrictive policy on the use of parenteral iron (transfusions, intravenous dextran-iron).
对111例慢性血液透析患者血清铁蛋白水平的演变进行了前瞻性研究。根据患者HLA分型中是否存在“血色素沉着症抗原”(HLA A3、B7或B14)将其分为两组。两组患者在开始透析前及第一年血清铁蛋白水平相似。相反,在血液透析的第二年和第三年,携带“血色素沉着症抗原”的组血清铁蛋白水平较高。在接受输血形式的胃肠外铁剂治疗或静脉注射右旋糖酐铁治疗的患者中观察到了这些差异,但接受口服铁剂治疗的患者未观察到。我们得出结论,HLA A3、B7或B14的血液透析患者发生铁过载的风险更大。然而,通过对胃肠外铁剂(输血、静脉注射右旋糖酐铁)的使用采取限制性政策,这种潜在风险可以降至最低。